Original Article

Efficacy of glutamine-enriched enteral feeding formulae in critically ill patients: a systematic review and meta-analysis of randomized controlled trials

Azadeh Mottaghi PhD¹, Maryam Zarif Yeganeh MSc¹, Mahdieh Golzarand MSc¹, Sara Jambarsang MSc², Parvin Mirmiran PhD³

¹Nutrition and Endocrine Research Center, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
²Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
³Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Nutrition and Endocrine Research Center, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Critically ill patients usually suffer from catabolic stress that could lead to malnutrition and nutritional support therefore is essential to maintain lean body mass, improve metabolic and immune response and decrease rate of mortality and comorbidity in these patients. This meta-analysis was aimed to evaluate effect of glutamine-enriched enteral nutrition in critically ill patients. In order to obtain randomized clinical trial studies (RCTs), international databases including MEDLINE and Google scholar and also electronic resources in Iran, including IRAN MEDEX, IRAN DOC, SID, Magiran were systematically searched without language and publication restriction before December 2014. The final included number of studies for meta-analysis was 10. The methodological quality of eligible studies was assessed by four investigators using the Jadad 5-point scale, a scale containing three items describing randomization, blinding and fate of participants. We analyzed data from the included studies using STATA version 12.0, and calculated a pooled odds ratio for dichotomous data and mean differences for continuous data with 95% confidence intervals (CIs). There was no significant difference in mortality in elevated pooled odds ratio values (p-value=0.070). A funnel plot was drawn for evaluation of publication bias, but none was found. The fixed effect model shows significant reduction in gut permeability in who received enteral feeding enriched with glutamine (-0.84, 95% CI=1.25 to -0.44), moreover the funnel plot did not show publication bias. Based on the available data, our meta-analysis showed that enteral glutamine (Gln) supplementation increased mortality rate, though non-significantly, but decreased gut permeability significantly.

Key Words: glutamine, enteral, immune-enhancing formula, critically ill patients, systematic review

INTRODUCTION

Critically ill patients usually suffer from catabolic stress that could lead to malnutrition.¹,² In these patients the risk of sepsis, infection, prolonged hospitalization, rate of mortality and intestinal permeability are high due to oxidative stress stimulation and immune system suppression.³,⁴ Nutritional support therefore is essential to maintain lean body mass, improve metabolic and immune response and decrease rate of mortality and comorbidity in these patients.¹,² Previous clinic studies have shown that parenteral and enteral nutrition are effective after surgery, trauma, infection and injuries,³ however, enteral nutrition is more beneficial than parenteral nutrition for improving intestinal endothelium function.⁵,⁶ Enteral nutrition plays a role in integrity and function of the gut tract via maintenance of mucosal mass and villi height, proliferation of enterocytes and production of gastrointestinal (GI) enzymes and hormones.¹

Studies have indicated that immune-enhancing formula decrease rate of mortality and infection. So, critically ill patients benefit from immune-enhancing nutrients, it had suggested that glutamine (Gln), an immune nutrient,⁵ is a dispensable amino acid that plays a pivotal role in the synthesis of neucolotides and supplying fuel for enterocytes. It contributes in musin production and integrity of GI membrane via synthesis of N-acetyl glucose amine and N-acetyl galactose amine.⁵,⁷ In stress and critically illness conditions consumption of Gln is higher than de novo synthesis and Gln plays a role as an indispensable

Corresponding Author: Dr Parvin Mirmiran, Nutrition Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Nutrition and Endocrine Research Center, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, PO Box 193-4763, Tehran, Iran.
Tel: +98-21-22432500; Fax: +98-21-22416264
Email: parvin.mirmiran@gmail.com

doi: 10.6133/apjcn.092015.24
amino acid. Animal studies have reported that Gln supplementation reduces risk of bacterial translocation, atrophy of intestinal mucosa, intestinal permeability and clinical infection. However, human clinical trials are inconsistent. Therefore, conducting a meta-analysis in order to clarification of glutamine effectiveness is required. This meta-analysis was aimed to evaluate effect of Gln-enriched enteral nutrition in critically ill patients.

METHODS

Literature search strategy

In order to obtain randomized clinical trial studies (RCTs), international databases including MEDLINE and Google scholar and also electronic resources in Iran, including IRAN MEDEX, IRAN DOC, SID, Magiran were systematically searched without language and publication restriction before December 2014. To achieve the maximum sensitivity of the search strategies and detect all RCTs using enteral feeding supplemented with glutamine in critically ill patients, we appropriately used keywords including: (enteral formula OR enteral nutrition OR enteral feeding) AND glutamine AND (critically ill OR intensive care unit OR severe illness). We also reviewed reference list of selected articles, conference proceedings to identify any articles and data not found using online methods.

Inclusion and exclusion criteria

Studies were eligible for inclusion in the present analysis if they met the following criteria: 1) Study design: Only RCTs with matched control group; 2) Patients characteristics: Only adults who were admitted to ICU or who had APACHE scores equal or above 10; 3) Intervention: Enteral formula supplemented with glutamine; and 4) Outcomes: Intestinal permeability, length of hospital stay, sepsis or infection rate, and mortality rate.

Studies were excluded for the following reason: 1) Studies on children and neonate; 2) Animal and laboratory studies; and 3) Studies with designs other than RCT.

Studies selection

Four investigators independently evaluated all abstracts of relevant studies. If abstracts potentially met the inclusion criteria, full texts of these were requested. Any disagreements were resolved through consensus.

Data extraction and quality assessment

Full texts of selected articles were obtained for quality assessment and the following data were extracted by four investigators: first author, year of publication, country, journal name, glutamine dosage, baseline characteristics and previously mentioned outcomes.

The methodological quality of eligible studies was assessed by four investigators using the Jadad 5-point scale, a scale containing three items describing randomization, blinding and fate of participants; we assigned 1 point if randomization was mentioned, 1 additional point if the method of randomization was appropriate and also we deducted 1 point if the method of randomization was inappropriate. Regarding blinding, we assigned 1 point if blinding was mentioned, 1 additional point if the method of blinding was appropriate and again we deducted 1 point if the method of blinding was inappropriate. Finally, we assigned 1 point if the fate of all participants in the trial was known, and if there were no data, the reason should have been stated. The quality scale ranged from 0 to 5. If Jadad score was ≥3 points, the article was considered as a high quality research and if Jadad score was ≤2 points, it was known as a low quality article.

Statistics

We analyzed data from the included studies using STATA version 12.0 (STATA Corporation, College Station, TX, USA), and calculated a pooled odds ratio for dichotomous data and mean differences for continuous data with 95% confidence intervals (CIs).

To assess heterogeneity across the studies, a statistical test for heterogeneity was performed based on the statistics. If the studies were shown to be homogeneous with p>0.05 for the Q test, the summary of OR was calculated by a fixed-effects model (the Mantel–Haenszel method) when between-study heterogeneity was absent. Otherwise, a random-effects model (the DerSimonian and Laird method) was used, publication bias was assessed using funnel plot techniques.

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to report the research protocol, outcomes and other

Figure 1. Flowchart illustrating the details of the search and study selection process.
relevant items in this systematic review.\textsuperscript{13}

**RESULTS**

**Included studies**

As shown in Figure 1, according to our inclusion criteria, in total 1652 potentially relevant articles were found. After deleting duplicate and irrelevant articles, post-reading titles and their abstracts, 48 articles remained for assessing eligibility. Of the 48 articles, 38 were excluded for following reasons: 14 articles did not have full-texts available, and the rest lacked relevant data. Finally, 10 RCTs ultimately included in our current systematic review.\textsuperscript{2-4,8,14-19} General information about the included articles is listed in Table 1. According to Jadad scores, nine of the trials were high quality and only one of these was low quality.

**Mortality**

A total of 10 eligible studies, 8 RCTs presented data of mortality. For each study, the odds ratio of mortality in patients with glutamine-enriched enteral feeding relative to control group was computed (Figure 2). Before carrying out the analysis and pooling the results, a heterogeneity hypothesis was tested using the chi square test, and found no significant heterogeneity between studies ($p$-value=0.62); hence we pooled estimation of the studies without adjustment for heterogeneity, using the fixed effect model. There was no significant difference in elevated pooled odds ratios ($p$-value=0.070). A funnel plot was drawn for evaluation of publication bias, but none was found (Figure 3).

**Length of hospitalization**

Six studies were used for analyzing data about length of hospitalization. The forest plot was used to illustrate mean hospital stay between the two groups in each study (Figure 4). Because of the heterogeneity between studies, the random effect model was used to combine the results of studies ($Q=9.87$, $p<0.001$, $I^2=95\%$). The results of the meta-analysis show no significant difference in mean hospital stay between the two treatment groups ($-0.19$, 95% CI=$-0.75$-$0.36$). A funnel plot showed evidence of publication bias (Figure 5). This can be due to the low sample size of studies and probably ignore some of the studies and also estimate the mean and variance.

**ICU stay length**

In 7 studies comprising 1267 patients, the author reported the ICU stay length. There was no significant difference was observed in any of the studies (Figure 6). A random effect model of studies found that no significant difference between two groups of patients about length of ICU stays ($-0.03$, 95% CI=$-0.53$-$0.47$). The results indicated heterogeneity between studies ($I^2=93\%$, $p=0.001$). A funnel plot also showed evidence of publication bias (Figure 7).

**Gut permeability**

Researchers in three studies reported gut permeability in an aggregate of 107 patients. Significant lower gut permeability was seen in patients who received enteral feeding enriched with glutamine compared to controls in the

---

\textbf{Table 1. General information about the included articles.}

<table>
<thead>
<tr>
<th>Study</th>
<th>Length (95% CI)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schulman et al.</td>
<td>(-0.65, -0.32)</td>
<td>17.4</td>
</tr>
<tr>
<td>Heyland et al.</td>
<td>(-0.25, -0.19)</td>
<td>18.5</td>
</tr>
<tr>
<td>Houdijk et al.</td>
<td>(0.14, 0.68)</td>
<td>15.8</td>
</tr>
<tr>
<td>Kumar et al.</td>
<td>(0.06, 0.12)</td>
<td>15.8</td>
</tr>
<tr>
<td>Mccarney et al.</td>
<td>(0.14, 0.68)</td>
<td>15.8</td>
</tr>
<tr>
<td>Hall et al.</td>
<td>(0.14, 0.68)</td>
<td>15.8</td>
</tr>
<tr>
<td>Overall</td>
<td>(0.14, 0.68)</td>
<td>15.8</td>
</tr>
</tbody>
</table>

---

\textbf{Figure 2. Odds ratios of mortality in patient with glutamine-enriched enteral feeding relative to control group.}

\textbf{Figure 3. Funnel plot of odds ratio of mortality in patient with glutamine-enriched enteral feeding relative to control group.}

\textbf{Figure 4. Mean difference of length of hospitalization in patient with glutamine-enriched enteral feeding relative to control group.}

\textbf{Figure 5. Funnel plot of mean difference of length of hospitalization in patient with glutamine-enriched enteral feeding relative to control group.}
Table 1. General information of included articles

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Population</th>
<th>Age</th>
<th>Formula</th>
<th>Gln</th>
<th>Control</th>
<th>Randomization Method</th>
<th>Length of supplementation</th>
<th>Jaded score</th>
<th>Glutamine dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boelens et al18</td>
<td>2004</td>
<td>Trauma</td>
<td>18-65</td>
<td>Alitra Q</td>
<td>17</td>
<td>17</td>
<td>Randomly allocated</td>
<td>5 days</td>
<td>4</td>
<td>30.5 g/100 g protein</td>
</tr>
<tr>
<td>Hall et al16</td>
<td>2003</td>
<td>Mixed ICU</td>
<td>Adults</td>
<td>Isocal + Gln</td>
<td>179</td>
<td>183</td>
<td>Randomly allocated</td>
<td>10 days</td>
<td>5</td>
<td>20 g/L</td>
</tr>
<tr>
<td>McQuiggan et al14</td>
<td>2008</td>
<td>Trauma</td>
<td>Adults</td>
<td>Glutasolve</td>
<td>10</td>
<td>10</td>
<td>Randomly allocated</td>
<td>10 days</td>
<td>3</td>
<td>0.5 g/kg/d</td>
</tr>
<tr>
<td>Heyland et al3</td>
<td>2013</td>
<td>Mixed ICU with organ failure</td>
<td>Adults</td>
<td>Dipeptiven</td>
<td>301</td>
<td>300</td>
<td>Randomly allocated</td>
<td>28 days</td>
<td>5</td>
<td>30 g/d</td>
</tr>
<tr>
<td>Schulman et al19</td>
<td>2005</td>
<td>Surgical and trauma</td>
<td>Adults</td>
<td>Replete + Gln</td>
<td>59</td>
<td>64</td>
<td>Sequential rotating assignment</td>
<td>13 days</td>
<td>3</td>
<td>0.6 g/kg/d (20-40 g/day)</td>
</tr>
<tr>
<td>Houdijk et al15</td>
<td>1998</td>
<td>Trauma</td>
<td>18-65</td>
<td>Alitra Q</td>
<td>29</td>
<td>31</td>
<td>Double-blind, randomized, prospective</td>
<td>15 days</td>
<td>3</td>
<td>30.5 g/100 g protein</td>
</tr>
<tr>
<td>Velasco et al8</td>
<td>2001</td>
<td>Surgical</td>
<td>19-74</td>
<td>ADN Nutricomp</td>
<td>7</td>
<td>8</td>
<td>Randomly allocated</td>
<td>8 days</td>
<td>1</td>
<td>0.15 g/kg/d</td>
</tr>
<tr>
<td>Conjero et al17</td>
<td>2002</td>
<td>SIRS</td>
<td>Adults</td>
<td>Juven</td>
<td>43</td>
<td>33</td>
<td>Computer generation randomization</td>
<td>10 days</td>
<td>4</td>
<td>30.5 g/L</td>
</tr>
<tr>
<td>Kumar et al4</td>
<td>2007</td>
<td>Peritonitis/ abdominal trauma</td>
<td>18-60</td>
<td>Hospital- made + Gln</td>
<td>63</td>
<td>57</td>
<td>Computer generation randomization</td>
<td>5 days</td>
<td>3</td>
<td>15 g/d</td>
</tr>
<tr>
<td>Jones et al2</td>
<td>1999</td>
<td>Mixed ICU</td>
<td>Adults</td>
<td>Protina MP + Gln</td>
<td>26</td>
<td>24</td>
<td>Block randomization by envelop</td>
<td>5 days</td>
<td>4</td>
<td>20 g/d</td>
</tr>
</tbody>
</table>

Table 2. Main results of RCTs

<table>
<thead>
<tr>
<th>Study</th>
<th>Gln</th>
<th>Control</th>
<th>Mortality (n)</th>
<th>Length of hospitalization (mean±SD)</th>
<th>Length of ICU stay (mean±SD)</th>
<th>Gut permeability (mean±SD)</th>
<th>Dependence on ventilator (mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gln</td>
<td>Control</td>
<td>Gln</td>
<td>Control</td>
</tr>
<tr>
<td>Boelens et al18</td>
<td>17</td>
<td>17</td>
<td>4/17</td>
<td>18.8±12.4</td>
<td>14.2±8.3</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Hall et al16</td>
<td>179</td>
<td>183</td>
<td>27/179</td>
<td>25±4.33</td>
<td>30±4.33</td>
<td>11±2</td>
<td>13±1.83</td>
</tr>
<tr>
<td>McQuiggan et al14</td>
<td>10</td>
<td>10</td>
<td>0/10</td>
<td>32±13.6</td>
<td>39.3±33.6</td>
<td>14.8±6.7</td>
<td>10.4±6.2</td>
</tr>
<tr>
<td>Heyland et al3</td>
<td>301</td>
<td>301</td>
<td>97/301</td>
<td>16±4.33</td>
<td>17.1±4.6</td>
<td>8.4±1.93</td>
<td>8.9±1.7</td>
</tr>
<tr>
<td>Schulman et al19</td>
<td>59</td>
<td>64</td>
<td>10/59</td>
<td>24.1±2.5</td>
<td>25.6±1.9</td>
<td>16.7±1.9</td>
<td>15.2±2.1</td>
</tr>
<tr>
<td>Houdijk et al15</td>
<td>29</td>
<td>31</td>
<td>2/29</td>
<td>32±3</td>
<td>27±4.3</td>
<td>0.04±0.011</td>
<td>0.075±0.018</td>
</tr>
<tr>
<td>Velasco et al8</td>
<td>7</td>
<td>8</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Conjero et al17</td>
<td>43</td>
<td>33</td>
<td>14/43</td>
<td>NR</td>
<td>NR</td>
<td>14±14.8</td>
<td>15±24.5</td>
</tr>
<tr>
<td>Kumar et al4</td>
<td>63</td>
<td>57</td>
<td>NR</td>
<td>11±6.75</td>
<td>9±20</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Jones et al2</td>
<td>26</td>
<td>24</td>
<td>12/26</td>
<td>NR</td>
<td>NR</td>
<td>11±12.5</td>
<td>16.5±15.3</td>
</tr>
<tr>
<td>Hernandez et al6</td>
<td>8</td>
<td>8</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>
A possible mechanism by which glutamine supplementation can decrease mortality rate was discovered. The mobilization of glutamine from protein stores; however, in the absence of glutamine, an experiment with growth hormone or IGF-1 therapy have indicated that Gln may be a conditionally essential amino acid in critically ill patients due to decrease in the plasma Gln levels of these patients;22 decrease of this amino acid in critical illness is associated with immune dysfunction;21 in sepsis and shock conditions, Gln acts as a stress signal in muscles.22

Results of our study mentioned that a non-significant increase occurred in mortality rate in critically ill patients, similar to which, some RCTs have demonstrated significant increase in mortality rate of critically ill patients. The possible mechanism of by which glutamine supplementation can decrease mortality rate was discovered. The bowel metabolizes less glutamine during sepsis, a response that may be related to the decrease in the amount of circulating insulin-like growth factor-1 (IGF-1) which is characteristic of sepsis; however, in the absence of glutamine supplementation, protein anabolic effects of growth hormone, which occur via IGF-1, have been associated with an increased mortality rate.23 A possible mechanism for this is profound glutamine depletion as a result of the mobilization of glutamine from protein stores; hence, there is interest in combining glutamine supplementation with growth hormone or IGF-1 therapy.24 On the other hand, an experimental Study have indicated that Gln by stimulating expression of heat shock proteins (HSPs) lead to reduction in mortality among critically ill patients.20 Despite the results of these studies, other studies have shown Gln supplementation had no effect on mortality rate, and it even caused increase in mortality rate. However, the possible reason for which was unclear.

In the present meta-analysis, gut permeability signify-
Glutamine-enriched enteral feeding formula and critically ill patients

and Enteral Nutrition (ESPEN) do not advise enteral Gln supplementation in critically ill patients due to lack of conclusive results. Future investigations to obtain conclusive results are recommended.

Chen et al in a meta-analysis on 17 RCTs have reported that Gln supplementation had no effect on mortality and length of hospitalization. As mentioned earlier in present meta-analysis, Gln supplementation had no any effect on length of hospitalization or length of ICU stay. In a review conducted by Tao et al on 53 RCTs, Gln supplementation decreased rate of infection (RR: 0.79, 95% CI: 0.71 to 0.78, p<0.001) and length of hospitalization (MD: -3.46 days, 95% CI: -4.61 to -2.32, p<0.001) in critically ill patients, compared with controls. No significant differences were found in mortality rate of critically ill patients and controls; moreover, both the above studies, RCTs that used Gln supplementation either parenteral or enteral were included in analysis; hence effects of enteral Gln on the outcomes of critically ill patients were unclear. Studies have indicated that parenteral administration of Gln can increase plasma Gln level to normal level, contrary to enteral Gln administration, which elevates plasma Gln levels slightly, indicating that the beneficial effects of Gln supplementation observed in this study, may be related mostly to parenteral Gln supplementation.

To the best of our knowledge, this systematic analysis is the first systematic review on the enteral use of Gln supplementation in critically ill patients. One of the strengths of our meta-analysis is that in this study we included RCTs which used just the enteral route of Gln supplementation. Another positive point of present study is that we had defined rigorous inclusion criteria such as excluding burned, malignant and head traumatic patients and incorporated original studies that enrolled large samples of patients in a randomized controlled design.

Some limitations of our analysis that need to be mentioned are; first, our meta-analyses could only take into account sources written in English. Second, some published trials only reported the median and range, using formulas; we estimated the mean and variance of the length of hospitalization and ICU stay. Third, there was heterogeneity in kinds of infection reported in patients and because of this the sample size was too small to have substantial power to explore the real association in any subgroup of infections.

**Conclusion**

In summary, based on the available data, our meta-analysis showed that enteral Gln supplementation increased mortality rate, though non-significantly, but decreased gut permeability significantly. According to recent RCTs and systematic meta-analysis studies on glutamine supplementation the Canadian Critical Care Practice Committee revised the Canadian Critical Care Nutrition Guidelines in 2013. The recommendation for parenteral Gln was downgraded from “strongly recommended” to “should be considered” with a warning, ie “strongly recommend that glutamine not be used in critically ill patients with shock and multi-organ failure”. The Committee also added use of strong caution in using enteral glutamine in all critically ill patients with shock.

![Figure 10](image1.png)

**Figure 10.** Mean difference of dependence on ventilator in patient with glutamine-enriched enteral feeding relative to control group.

![Figure 11](image2.png)

**Figure 11.** Funnel plot of mean difference of dependence on ventilator in patient with glutamine-enriched enteral feeding relative to control group.
and multi-organ failure because of the results of the recent multicenter study that showed severe complication with the use of combined enteral and parenteral glutamine. The current meta-analysis did not provide sufficient evidence for the use of gln-enriched enteral feeding for critically ill patients.

ACKNOWLEDGEMENTS
This study was supported by the Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, and Islamic Republic of Iran. The authors also wish to acknowledge Ms. Nilofar Shiva for critical editing of English grammar and syntax of this manuscript. The Ethics Committee of Shahid Beheshti University of Medical Sciences approved this study.

AUTHOR DISCLOSURES
The authors declare no conflict of interest.

REFERENCES
Glutamine-enriched enteral feeding formula and critically ill patients


Original Article

Efficacy of glutamine-enriched enteral feeding formulae in critically ill patients: a systematic review and meta-analysis of randomized controlled trials

Azadeh Mottaghi PhD¹, Maryam Zarif Yeganeh MSc¹, Mahdieh Golzarand MSc¹, Sara Jambarsang MSc², Parvin Mirmiran PhD³

¹Nutrition and Endocrine Research Center, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
²Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
³Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Nutrition and Endocrine Research Center, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

谷氨酰胺强化的肠内营养配方对危重症患者的疗效：随机对照试验的系统综述和 meta 分析

重症患者通常患有代谢应激可以导致营养不良，因此营养支持对保持瘦体重、改善代谢和免疫反应、降低这些病人的死亡率和并发症是必不可少的。本 meta 分析的目的是评估谷氨酰胺强化的肠内营养对重症患者的疗效。为了获得随机临床试验研究（RCTs），我们检索了 MEDLINE 和谷歌学术等国际数据库，以及 MEDEX、IRANDOC、SID 和 Magiran 等电子资源中 2014 年 12 月份以前的文献，不受出版语言限制。最终有 10 个研究纳入了 meta 分析。由四个研究者采用包括随机化、盲法和研究对象的合格性三个项目的 Jadad5 点量表来评估合格研究的方法学质量。我们用 STATA12.0 分析纳入研究的数据，计算二分类变量的比值比和连续性变量的标准差及它们的 95% 置信区间（CIs）。死亡率在升高和合并比值比中无显著差异（p-value=0.070）。在绘制漏斗图中没有发表偏倚。固定效应模型显示接受谷氨酰胺强化的肠内营养的患者肠道通透性显著降低（-0.84, 95% CI=-1.25 到-0.44），而且漏斗图显示没有发表偏倚。根据现有的资料，我们的 meta 分析表明，肠内谷氨酰胺补充增加死亡率，虽然没有显著性，但显著降低了肠道通透性。

关键词：谷氨酰胺、肠内、免疫增强配方、危重症患者、系统综述